FDA Drug Recalls

Recalls / Class II

Class IID-0809-2021

Product

Chantix (varenicline) tablets 0.5mg, 56 Tablets, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 0069-0468-56.

Brand name
Chantix
Generic name
Varenicline Tartrate
Active ingredient
Varenicline Tartrate
Route
Oral
NDCs
0069-0468, 0069-0469, 0069-0471
FDA application
NDA021928
Affected lot / code info
Lots , CY6861, DM9007, DM9008, EN5725, EN8362, EN8467 EXPIRATION DATE: January 2022 - May 2023

Why it was recalled

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Recalling firm

Firm
Pfizer Inc.
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Notification channel
Press Release
Type
Voluntary: Firm initiated
Address
235 East 42nd Street, New York, New York 10017-5703

Distribution

Distribution pattern
Nationwide

Timeline

Recall initiated
2021-08-13
FDA classified
2021-09-17
Posted by FDA
2021-09-29
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0809-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Chantix · FDA Drug Recalls